Fate Therapeutics (FATE) FT516 Update 'Good, But Still Early' - Cowen
Tweet Send to a Friend
Cowen analyst Tyler Van Buren reiterated an Outperform rating on Fate Therapeutics (NASDAQ: FATE) after the incremental FY516 update, which ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
